Research Article
The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study
Table 3
AUROC for Velacur™ assessments of LSM and attenuation parameters in different subject cohorts.
| | Number of subjects | AUROC Velacur E (95% CI) | AUROC Velacur ACE (95% CI) |
| Healthy controls vs. patients | 54 vs. 79 | 0.9379 (0.8805-0.9636) | 0.9011 (0.8451-0.9454) | Healthy control vs. NAFLD patients | 54 vs. 54 | 0.9156 (0.8617-0.9592) | 0.9280 (0.8637-0.9636) | Healthy control vs. HCV SVR patients | 54 vs. 25 | 0.9859 (0.9492-0.9969) | 0.8430 (0.6831-0.9137) | Using kPa and >8 kPa | 62 vs. 71 | 0.9137 (0.8648-0.9564) | N/A | Using dB/m and >238 dB/m | 62 vs. 71 | N/A | 0.8458 (0.7753-0.9150) |
|
|